Search Results - Therapeutics

57 Results

Sort By:

PD1+CD38+ CD8 T-cells, a marker for anti-PD1 therapy resistance and selection marker for treatment or continuation of treatment of patients, and a target to reverse resistance

PD1+CD38+ CD8 T-cells, a marker for anti-PD1 therapy resistance and selection marker for treatment or continuation of treatment of patients, and a target to reverse resistance Current state of the artA number of new checkpoint inhibitors are used in cancer therapy. PD-1 inhibitors such as Pembrolizumab (Keytruda), Nivolumab (Opdivo), and Cemiplimab...

Published: 8/29/2024 | Inventor(s): Samir Khleif, Vivek Verma, Seema Gupta

Keywords(s):

Category(s): Therapeutics

Crosslinking proteins to RBCs (protein-RBCs) with EDC can be improved with sulfo-NHS +/- sulfo-NHS-acetate

Intravenous infusion of protein/peptide antigens linked to lymphocytes with ethylene carbodiimide (EDC) is a highly efficient method for inducing peripheral, antigen-specific T cell tolerance for the treatment of autoimmune disease. Likewise, red blood cells (RBC) can be used to deliver protein/peptide antigens for treatment of autoimmune disease. EDC...

Published: 7/11/2023 | Inventor(s): Ryan Jajosky, Rafal Pacholczyk, Gurmukh Singh

Keywords(s):

Category(s): Therapeutics

Antibody specific for PKG-1alpha nitration

Scientists at AU identified that nitration of PKG-1α in tyrosine 247 attenuates the catalytic activity of PKG-1 α, which plays a critical role in the development of vascular dysfunction in pulmonary hypertension and other vascular pathologies. The inventors developed the humanized monoclonal antibody or antigen-binding fragment for detecting...

Published: 3/31/2022 | Inventor(s): Stephen Black

Keywords(s):

Category(s): Diagnostics, Therapeutics, Antibody

Effect of GHRH Antagonists in Type 2 Diabetes and Obesity

The current state of the art Triglyceride-rich-lipoproteins (TRL), that are generated in the small intestine as chylomicrons and the liver as very-low-density lipoprotein (VLDL), and their remnants represent an important risk factor for cardiovascular disease (DVD) in people with diabetes, obesities, or metabolic syndrome. The problems with the current...

Published: 3/9/2022 | Inventor(s): Maritza Romero Lucas, Rudolf Lucas, Neal Weintraub, Andrew Schally, Renzhi Cai

Keywords(s):

Category(s): Therapeutics

Use of arginase 1 as a treatment for retinopathy

The current state of the art Ischemia retinopathies cause retinal neurovascular injury and are a primary contributor to blinding disease that affects neonates (retinopathy of prematurity), working-age adults (diabetic retinopathy), and the elderly (branch vein occlusion and age-related macular degeneration). The problems with the current art Despite...

Published: 11/11/2022 | Inventor(s): Ruth Caldwell, William Caldwell, Abdelrahman Fouda

Keywords(s):

Category(s): Therapeutics

Title: Engineered Exosome Delivery System to detect and deplete pro-tumorigenic macrophages

The current state of the art: Despite the advancement in immunotherapy and other targeted therapy for the treatment of cancer, the success rate remains low in solid tumors. Targeting the tumor microenvironment (TME) is a new promising treatment strategy. Infiltrated in TME, tumor-associated macrophages, especially CD206 positive M2 macrophages, play...

Published: 7/12/2022 | Inventor(s): Ali Arbab, Mohammad Rashid, Thaiz Borin, Roxan Ara

Keywords(s):

Category(s): Diagnostics, Therapeutics

Novel TREM1 inhibitor for pathological inflammatory response

The current state of the art Trigging receptor expressed on myeloid cell 1 (TREM-1) plays a critical role in the pathogenesis of acute and chronic cardiovascular conditions, and is a crucial mediator of septic shock, especially, in cytokine release syndrome. Inhibiting TREM-1 is a promising therapeutic candidate for TREM-related diseases such as inflammatory...

Published: 4/7/2023 | Inventor(s): Anatolij Horuzsko, Iryna Lebedyeva, Thomas Albers, Ashwin Ajith

Keywords(s):

Category(s): Therapeutics

Adenovirus Survivin for Detection or Treatment of Uterine Leiomyosarcoma

The Current State of Art Uterine sarcoma, though with very low incidence (4% of uterine cancer), has a high malignant degree and poor prognosis. Leiomyosarcoma is the most common type of uterine sarcoma and usually occurs in women over 40 years. Proper differentiation between benign leiomyoma and malignant uterine leiomyosarcoma can dramatically improve...

Published: 5/25/2021 | Inventor(s): Ayman Al-Hendy, Mostafa Khater

Keywords(s):

Category(s): Diagnostics, Methods, Therapeutics

Deep Brain Stimulation for the Treatment of Non-Alzheimer's Dementia

The current state of the art The current treatment option for Alzheimer’s disease and aging related dementia are focused on the alleviation of symptoms and managing cognition. Degeneration of cholinergic neurons is one of the mechanisms leading to cognition declination. Therefore, aging and Alzheimer’s dementia is commonly treated with...

Published: 4/7/2023 | Inventor(s): Cole Giller, David Blake, David Hess, Alvin Terry, Jr., John Morgan, Gregory Lee, Jonathan Crawford, Ruifeng Liu, Christos Constantinidis

Keywords(s):

Category(s): Therapeutics

Methods and Compositions for Treating Neurodegenarative Diseases

The current state of the art: Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and multiple sclerosis pose devastating threats to both patients and their caregivers. Although palliative measurements are available to manage the disease symptoms, effective...

Published: 11/28/2022 | Inventor(s): Robert Yu, Yutaka Itokazu

Keywords(s):

Category(s): Therapeutics

1 2 3 4 5 6